Citius Pharmaceuticals, Inc. (CTXR)
$0.48-2.04%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5M
- Beta
- 1.00
- P/E (TTM)
- -0.23
- Short % float
- 53.06%
- Days to cover
- 30.5
- SI change
- +0.5%
- 1W
- +0.00%
- 1M
- -15.79%
- vs SPY 1W
- +0.14%
- vs SPY 1M
- -18.30%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 1
- VALUE
- 19
- GROWTH
- 26
- GARP
- 3
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-40.3%
REV YoY-
ROE-67.1%
EPS YoY-
ROA-32.5%
GROSS20
OP-864
NET-651
[VALUATION]
P/E TTM-0.23
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.19
P/FCF-
EV/EBITDA-0.06
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E10.77
ALTMAN Z-
CURR RATIO0.84
ND/EBITDA-
BETA1.00
Company news
FAQ
- What is LOPJLB’s current signal on CTXR?
- LOPJLB’s latest quantitative signal on Citius Pharmaceuticals, Inc. (CTXR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CTXR in?
- Citius Pharmaceuticals, Inc. (CTXR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Citius Pharmaceuticals, Inc. (CTXR) do?
- Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products withi…